Ying

Yingli Pharma is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, focused on the discovery and development of innovative small molecule therapeutics for oncology and autoimmune diseases. The company's lead candidate, linperlisib (YY-20394), is a highly selective PI3K-delta inhibitor currently in late-stage clinical trials for various hematological malignancies, including follicular lymphoma and marginal zone lymphoma. Beyond its lead program, Yingli Pharma is advancing a diverse pipeline of inhibitors targeting FGFR, BET, and TLR7/8 pathways. The company leverages its internal R&D capabilities to develop high-potency, low-toxicity drugs aimed at addressing significant unmet medical needs in the global market. Yingli Pharma has established strategic partnerships with major industry players to accelerate the commercialization and clinical reach of its portfolio.